I can't quite figure out if this company is planning to grow by manufacturing generics or by developing new products based on thier own research. Any comments, especially on the potential of each approach ?
A WBN-SUPG cyberstation is up an running at http://www.wbn.com under the direction of Jay Abella who is on everyone's short list for Internet All America biotech analyst. Jay delves into SUPG's unique strategy.
I think they are into making money however they can. This team of people weren't born yesterday and they know their business and are not likely to make false steps on what drugs to research or manufacture. But I have seen doubts expressed about their experience constructing the whole apparatus need to take ideas and turn them into revenue. Time will tell. I like 'em.